GLP-1 (glucagon-like peptide) medications, such as Ozempic and Wegovy, have seen a surge in popularity over the past few ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

Despite weight loss and glycemic control, experts caution that type 2 diabetes remission is not a cure and that pancreatic ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

Experts explain if Ozempic causes hair loss, and how the medication may indirectly lead to weight loss-related hair loss due ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

The demand for glucagon-like peptide 1 (GLP-1) receptor agonists for overweight/obesity has created a clinical conundrum for ...